DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Chad Michael Murray - 1 Murray - 1 Britt Robertson - 1 Guillermo del Toro's - 1 Jude's Children's - 1 baring - 1 Numéro - 1 Sarah Roemer - 1
Top related locs:
St Jude's Numéro Netherlands Los Angeles Samos London U.S
Top related orgs:
Netflix - 1 Merck - 1 New York Stock Exchange - 1 Infectious - 1 Research - 1 Sanofi - 1 AstraZeneca - 1 Pfizer - 1

Search resuls for: "Jude's"


4 mentions found


☆ Chad Michael Murray says his 'stripper Christmas movie' is family-friendly: 'I want to bring joy and happiness as much as I can'
  + stars: | 2024-12-03 | by ( Caralynn Matassa | ) www.businessinsider.com   time to read: +3 min
Advertisement"The Merry Gentlemen" is one of Netflix's latest original Christmas movies. It stars Chad Michael Murray as a small-town handyman who joins a male dance revue to save a local bar. Chad Michael Murray stripped down for his new Netflix movie, but it's for a good cause. But despite the semi-nudity, Murray feels his "stripper Christmas movie" is very much a family-friendly holiday film. Chad Michael Murray in the Netflix movie "The Merry Gentlemen."
Persons: Chad Michael Murray, Murray, Britt Robertson, Guillermo del Toro's, Jude's Children's, baring, Numéro, Sarah Roemer, Katrina Marcinowski, Hilary Duff Organizations: Netflix Locations: St, Jude's, Numéro Netherlands
☆ Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
  + stars: | 2024-10-17 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Merck plans to discuss the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season, according to a release. The trial examined the safety and efficacy of a single dose of the treatment, clesrovimab, in healthy preterm and full-term infants entering their first RSV season. Results were consistent through both the five-month and six-month time points in the trial, Merck said. Merck's clesrovimab could potentially compete against a similar treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide last RSV season due to unprecedented demand. But Merck's treatment can be administered to infants regardless of their weight, which the company said may offer convenience in terms of dosing.
Persons: Merck, Clesrovimab, Dr, Octavio Ramilo, Ramilo, Merck's Organizations: Merck, New York Stock Exchange, Infectious, Research, Sanofi, AstraZeneca, Pfizer, GSK Locations: Los Angeles, St
☆ Here's an exclusive look at the 17-slide presentation that startup Jude used to raise $4.24 million to help boomers who need bladder help
  + stars: | 2023-09-21 | by ( Samantha Stokes | ) www.businessinsider.com   time to read: +2 min
Move over, millennials: one startup founder is betting big that baby boomers are a largely untapped goldmine for discreet undergarments and supplements. With the seed funding, Jude plans to expand into the U.S., selling at the intersection of bladder care, senior healthcare, and women's health. The combination of healthcare, eldercare, and women's health proved to be crucial when Jude tried to line up investors. Take a look at the 17-slide presentation Jude used to raise $4.24 million in seed funding. Jude - healthcare brand for a new age JudeJudeJudeJudeJudeJudeJudeJudeJudeJudeJudeJudeJudeJudeJudeJude
Persons: Jude, Eka, Fiono Pathiraja, Christa Galli, Peony Li, Jude Jude Jude Jude Jude Jude Jude Jude Jude Jude Jude Jude Jude Jude Jude Jude Organizations: Christa Galli Ventures Locations: Samos, London, U.S
☆ U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead
  + stars: | 2022-11-07 | by ( Blake Brittain | Thomson Reuters | Blake Brittain Reports On Intellectual Property Law | ) www.reuters.com   time to read: +3 min
WASHINGTON, Nov 7 (Reuters) - The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc (GILD.O) subsidiary Kite Pharma Inc over a lymphoma drug. The justices turned away Juno's appeal of a lower court's ruling throwing out the award in the litigation over Kite's biologic drug Yescarta, in a case that could have repercussions for the cutting-edge biologic drug industry. Juno and Sloan Kettering Institute for Cancer Research sued Kite in 2017 in federal court in Los Angeles, accusing it of copying technology that the institute licenses to Juno. Juno and Sloan Kettering have told the Supreme Court that the Federal Circuit's decision to invalidate the patent and other rulings against biologic patents have been "devastating for innovation." On Nov. 4, the Supreme Court took up another patent case involving biologic drugs, agreeing to hear Amgen's bid to revive patents on its cholesterol drug Repatha.
0 next >>
Total: 4